Synthesis, In Vivo Anticonvulsant Activity Evaluation and In Silico Studies of Some Quinazolin-4(3H)-One Derivatives.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Thiazol-4-yl-Methylthio-Quinazolin-4(3H)-ones as Anticonvulsant Compounds: Chemical Design, Computational Studies, and Biological Evaluation.International journal of molecular sciences · 2026
   Article
2. Design, synthesis, and in vivo antiepileptic evaluation of novel quinazolinone-phthalimide derivatives.Scientific reports · 2026
   Article
3. From 2-Azido Products to Complex Nitrogen Heterocycles: The Versatile Ugi MCR in Modern Synthesis.Current organic synthesis · 2026
   Article
4. Recent advances in quinazolinone derivatives: structure, design and therapeutic potential.Future medicinal chemistry · 2025
   Review
5. Exploring the Pharmacological Potential of Carrageenan Disaccharides as Antitumor Agents: An In Silico Approach.Marine drugs · 2024
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

12 authors.

Funding

Abstract

Indexed as